FOXO
FOXO TECHNOLOGIES INC.
-0.01 (-10.63%)0.10USD267成交股數166K市值–本益比(近四季)0.0股價營收比-9.7%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 4.7M-10% | 5.2M+63% | 4.4M+270% | 3.5M+12815% | 5.2M+72579% | 3.2M+2774% | 1.2M+11866% | 27K+129% | 7K | 110K | 10K | 12K |
| 營業成本 | – | – | – | – | – | – | – | – | – | 37K | 70K | 12K |
| 毛利 | – | – | – | – | – | – | – | – | – | 73K | −60K | 0.00 |
| 毛利率 | – | – | – | – | – | – | – | – | – | 66.2% | -600.0% | 0.0% |
| 研發費用 | 24K | 36K | 35K | 77K | 40K | 30K | 44K | 103K | 165K | −25K | 283K | 333K |
| 銷售管理費用 | 2.7M | 2.9M | 3.5M | 2.5M | 2.6M | 2.8M | 1.7M | 1.5M | 988K | 4.3M | 4.7M | 4.0M |
| 營業利益 | 8.7M+1443% | −277K-82% | −8.5M+744% | −860K-46% | 567K-148% | −1.5M-58% | −1.0M-71% | −1.6M-79% | −1.2M | −3.7M | −3.5M | −7.6M |
| 營業利益率 | 185.5% | -5.4% | -191.6% | -24.2% | 10.9% | -48.8% | -84.0% | -5,785.7% | -16,416.0% | -3,339.9% | -35,070.0% | -63,375.0% |
| 稅後淨利 | 8.1M-1659% | −1.5M+136% | −9.4M+384% | −1.9M-13% | −522K-65% | −616K-84% | −1.9M-47% | −2.2M-81% | −1.5M | −3.9M | −3.7M | −11.3M |
| 淨利率 | 172.6% | -28.1% | -212.5% | -52.9% | -10.0% | -19.4% | -162.7% | -7,872.7% | -20,946.9% | -3,498.5% | -36,600.0% | -94,108.3% |
| 稀釋 EPS | – | – | – | – | – | – | – | – | – | – | – | – |
| 稀釋股數 | – | – | – | – | – | – | – | – | – | – | – | – |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 58K | 66K | 207K | 629K | 322K | 17K | 34K | 33K | 3K | 38K | 42K | 215K |
| 應收帳款 | 4.1M | 3.9M | 2.5M | 3.2M | 4.9M | 2.7M | 2.0M | 276K | – | – | – | – |
| 存貨 | 160K | 189K | 184K | 8K | – | – | – | – | – | – | – | – |
| 總資產 | 45.9M | 45.8M | 44.6M | 52.1M | 50.0M | 47.0M | 42.7M | 6.9M | 3.0M | 726K | 3.1M | 4.0M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 45.0M | 36.2M | 33.5M | 32.0M | 36.3M | 37.4M | 60.2M | 23.1M | 17.9M | 14.8M | 14.2M | 11.1M |
| 股東權益 | 988K | 9.7M | 11.1M | 20.2M | 13.7M | 9.7M | −17.5M | −16.1M | −14.9M | −14.1M | −11.1M | −7.0M |
| 負債比 | 98.0% | 79.0% | 75.2% | 61.3% | 72.7% | 79.5% | 141.1% | 334.1% | 598.9% | 2,043.1% | 454.6% | 273.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −578K-57% | – | – | – | −1.3M | – | – | −406K | – | – | – |
| 資本支出 | – | 4K | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | −582K | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | – | 171K | – | – | 2K | 143K | – | 52K | 260K | – | – | 247K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -11.3% | – | – | – | – | – | – | – | – | – | – |
營收拆解 2023 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2023 年度 · 145K
| All Other Segments | 145K | 100.0% | -71.6% |
|---|
產品／服務2023 年度 · 145K
| Epigenetic Biomarker Services | 99K | 68.3% | -75.3% |
|---|---|---|---|
| Epigenetic Biomarker Royalties | 27K | 18.6% | -67.5% |
| Life Insurance Commissions | 19K | 13.1% | -32.1% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 16.4M | +304.0% | −12.4M | -75.9% | – | −3.9M |
| FY2024 | 4.1M | +2688.6% | −12.4M | -306.2% | – | – |
| FY2023 | 145K | -71.6% | −26.5M | -18,205.2% | – | – |
| FY2022 | 511K | +325.8% | −95.3M | -18,640.9% | – | −23.9M |
| FY2021 | 120K | – | −38.5M | -32,073.3% | – | −15.2M |